Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2
Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, Kwang Su Kim, Joohyeon Woo, Kaho Shionoya, Kana Tsuchimoto, Shoya Iwanami, Saya Moriyama, Hitomi Kinoshita, Souichi Yamada, Yudai Kuroda, Tsukasa Yamamoto, Noriko Kishida, Shinji Watanabe, Hideki Hasegawa, Hideki Ebihara, Tadaki Suzuki, Ken Maeda, Shuetsu Fukushi, Yoshimasa Takahashi, Shingo Iwami, Koichi Watashi
Topics & Concepts
AntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)Neutralizing antibodyAntiviral treatmentAntibody responseDrugAntiviral drug2019-20 coronavirus outbreakBiologyVirusImmunologyMedicinePharmacologyPathologyChronic hepatitisInfectious disease (medical specialty)OutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesSARS-CoV-2 detection and testing